CTRI/2022/08/045067招募中未知
A Prospective, Multi-Center, Randomized, Double-Blind, Parallel, Placebo- Controlled Study to Evaluate Efficacy and Safety of Berberis aristata on Memory and Cognitive Performance in Adult Human Subjects with Mild Cognitive Impairment
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult male/female human participants of ââ?°Â¥ 18 and ââ?°Â¤55 years of age.
- •2.Participants with BMI ââ?°Â¥ 18.5 kg/m2 and ââ?°Â¤ 29.9 kg/m2.
- •3.Participants with Mini-Mental State Examination (MMSE) score 19 to 26 indicating mild cognitive impairment.
- •4.Participants who agree to maintain their usual dietary habits throughout the trial period.
- •5.Participants who agree to maintain their usual level of activity, i.e., maintain their usual lifestyle throughout the trial period.
排除标准
- •1.Participants Ã?â?? 18 or Ã?Æ? 55 years of age.
- •2.Participants having hypersensitivity or history of allergy to the study product or any of its ingredients.
- •3.Participants suffering from moderate to severe fatigue or having chronic fatigue syndrome.
- •4.Participants suffering from malignant disease or any concomitant end-state organ disease and/or laboratory abnormalities considered by investigators to be risky or that could interfere with data collection.
- •5.Participants suffering from a metabolic disorder (uncontrolled diabetes, uncontrolled thyroidal condition) and/or from severe chronic disease (cancer, renal failure, HIV, immunodeficiency, hepatic or biliary disorders, arthritis, uncontrolled cardiac disease) or from a disease found to be inconsistent with the conduct of the study by the investigator.
研究者
相似试验
已完成
不适用
This is a clinical trial to compare clinical efficacy, safety and tolerability of generic Diclofenac Sodium Topical Gel 1%, with Voltaren® Gel (a Diclofenac Sodium Topical Gel 1%) and Vehicle of Diclofenac Sodium Topical Gel 1% in subjects with osteoarthritis(degenerative joint disease) of the kneeCTRI/2015/09/006149Cipla Limited990
已完成
3 期
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA * Intervention Trial)heart and vessel disease1001108210047066cardiovascular diseaseNL-OMON46966Amarin Pharma Inc.1,700
进行中（未招募）
1 期
ot applicableCardiovascular Disease or at High Risk for Cardiovascular DiseaseMedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2011-004726-10-NLAmarin Pharma Inc.7,990
已完成
不适用
A Multi-Center, Prospective, Randomized, Double-Blind, Active-Controlled, Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Fexuprazan in Patients with Laryngopharyngeal Reflux DiseaseKCT0007251Asan Medical Center150
招募中
3 期
A study to determine the effectiveness and safety of AMR101 in reducing the risk of cardiovascular events (e.g. stroke, heart attack, unstable angina) in patients with high triglyceride levels and who are on statin treatments.CTRI/2012/05/002653Amarin Pharma Inc7,990